Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling
Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling
The investigators are doing this research study to compare the pharmacokinetics (PK) (rate of
 absorption) of insulin lispro (Humalog), insulin aspart (Novolog), and insulin glulisine
 (Apidra) within individual subjects.

 Additionally, the investigators will perform a preliminary feasibility evaluation of a
 minimally invasive continuous insulin monitoring (CIM) device and its use to derive PK
 parameters in human subjects.
Inclusion Criteria:

 -  Age 18 years or older with clinical type 1 diabetes for at least five years

 -  Diabetes managed using an insulin infusion pump and rapid- or very-rapid-acting
 insulins including insulin aspart (NovoLog), insulin lispro (Humalog), and insulin
 glulisine (Apidra).

 -  Ability to consume a sufficient amount of carbohydrates over 2-3 hours to cover 9
 units of rapid acting insulin

 Exclusion Criteria:

 -  Unable to provide informed consent

 -  Unable to comply with study procedures

 -  Inadequate venous access as determined by study nurse or physician at time of
 screening.

 -  Pregnancy

 -  History of gastric banding, gastric bypass, or other gastrointestinal condition that
 may prevent a subject from consuming a normal sized meal

 -  Hemoglobin <13.5 for men, < 12 for women